Arecor Therapeutics plc
AREC.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £2,003 | £3,058 | £1,995 | £2,904 |
| % Growth | -34.5% | 53.3% | -31.3% | – |
| Cost of Goods Sold | £1,675 | £3,510 | -£220 | £195 |
| Gross Profit | £328 | -£672 | £2,215 | £3,205 |
| % Margin | 16.4% | -22% | 111% | 110.4% |
| R&D Expenses | £1,279 | £954 | £1,725 | £3,119 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £2,112 | £1,177 | £3,416 | £4,538 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £3,280 | £0 | -£195 |
| Operating Expenses | £3,391 | £5,411 | £5,141 | £7,462 |
| Operating Income | -£3,063 | -£2,803 | -£7,894 | -£3,611 |
| % Margin | -152.9% | -91.7% | -395.7% | -124.3% |
| Other Income/Exp. Net | £521 | -£3,024 | £3,103 | -£489 |
| Pre-Tax Income | -£2,542 | -£5,827 | -£4,791 | -£4,100 |
| Tax Expense | -£34 | -£231 | -£151 | -£74 |
| Net Income | -£2,508 | -£5,596 | -£4,640 | -£4,026 |
| % Margin | -125.2% | -183% | -232.6% | -138.6% |
| EPS | -0.066 | -0.15 | -0.15 | -0.13 |
| % Growth | 55.7% | 0% | -15.4% | – |
| EPS Diluted | -0.066 | -0.15 | -0.15 | -0.13 |
| Weighted Avg Shares Out | 37,757 | 37,760 | 30,627 | 30,626 |
| Weighted Avg Shares Out Dil | 37,757 | 37,760 | 30,627 | 30,626 |
| Supplemental Information | – | – | – | – |
| Interest Income | £27 | £46 | £55 | £240 |
| Interest Expense | £8 | £10 | £12 | £10 |
| Depreciation & Amortization | £113 | £220 | £226 | £148 |
| EBITDA | -£2,421 | -£5,597 | -£4,553 | -£4,073 |
| % Margin | -120.9% | -183% | -228.2% | -140.2% |